Clearside Biomedical, Inc. (NASDAQ:CLSD) Director Purchases $13,800.00 in Stock

Clearside Biomedical, Inc. (NASDAQ:CLSD) Director Clay Thorp bought 15,000 shares of Clearside Biomedical stock in a transaction dated Monday, February 24th. The stock was acquired at an average cost of $0.92 per share, with a total value of $13,800.00. Following the completion of the acquisition, the director now directly owns 176,141 shares of the company’s stock, valued at approximately $162,049.72. The trade was a 9.31 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website.

Clearside Biomedical Trading Down 7.4 %

Shares of CLSD opened at $0.88 on Tuesday. The firm’s 50-day moving average is $0.97 and its two-hundred day moving average is $1.07. Clearside Biomedical, Inc. has a twelve month low of $0.80 and a twelve month high of $2.12. The firm has a market capitalization of $66.74 million, a P/E ratio of -1.96 and a beta of 2.22.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in CLSD. Investor s Fiduciary Advisor Network LLC acquired a new position in Clearside Biomedical during the fourth quarter worth about $32,000. Johnson & Johnson acquired a new position in Clearside Biomedical during the third quarter worth about $105,000. Northern Trust Corp grew its position in Clearside Biomedical by 24.0% during the fourth quarter. Northern Trust Corp now owns 165,499 shares of the company’s stock worth $157,000 after buying an additional 32,048 shares during the period. Finally, Geode Capital Management LLC grew its position in Clearside Biomedical by 4.5% during the fourth quarter. Geode Capital Management LLC now owns 764,058 shares of the company’s stock worth $726,000 after buying an additional 32,672 shares during the period. 18.75% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

CLSD has been the topic of a number of recent analyst reports. HC Wainwright reiterated a “buy” rating and set a $6.00 price target on shares of Clearside Biomedical in a research note on Thursday, November 14th. Needham & Company LLC reiterated a “buy” rating and set a $6.00 price target on shares of Clearside Biomedical in a research note on Wednesday, November 13th. StockNews.com upgraded shares of Clearside Biomedical from a “sell” rating to a “hold” rating in a research note on Thursday, December 12th. Finally, Chardan Capital reiterated a “buy” rating and set a $6.00 price target on shares of Clearside Biomedical in a research note on Friday, November 15th. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat, Clearside Biomedical currently has a consensus rating of “Moderate Buy” and a consensus target price of $5.33.

About Clearside Biomedical

Clearside Biomedical, Inc, a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD.